Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks (Nasdaq: ZYME), a clinical-stage biotechnology company focused on developing multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases, has announced its participation in two major upcoming investor conferences.
The company will be present at the Needham 24th Annual Virtual Healthcare Conference, where management will conduct one-on-one meetings and deliver a presentation on April 8 at 9:30 am ET. Additionally, Zymeworks will participate in the Stifel 2025 Virtual Targeted Oncology Forum on April 9 at 12:30 pm ET, featuring one-on-one meetings and a fireside chat.
Zymeworks (Nasdaq: ZYME), un'azienda biotecnologica in fase clinica focalizzata nello sviluppo di bioterapeutici multifunzionali per il cancro, l'infiammazione e le malattie autoimmuni, ha annunciato la sua partecipazione a due importanti conferenze per investitori in arrivo.
L'azienda sarà presente alla Needham 24th Annual Virtual Healthcare Conference, dove la direzione condurrà incontri individuali e presenterà un intervento l'8 aprile alle 9:30 ET. Inoltre, Zymeworks parteciperà al Stifel 2025 Virtual Targeted Oncology Forum il 9 aprile alle 12:30 ET, con incontri individuali e una chiacchierata informale.
Zymeworks (Nasdaq: ZYME), una empresa biotecnológica en etapa clínica centrada en el desarrollo de bioterapéuticos multifuncionales para el cáncer, la inflamación y enfermedades autoinmunes, ha anunciado su participación en dos importantes conferencias para inversores próximas.
La empresa estará presente en la Needham 24th Annual Virtual Healthcare Conference, donde la dirección realizará reuniones individuales y presentará una charla el 8 de abril a las 9:30 am ET. Además, Zymeworks participará en el Stifel 2025 Virtual Targeted Oncology Forum el 9 de abril a las 12:30 pm ET, con reuniones individuales y una charla junto a la chimenea.
Zymeworks (Nasdaq: ZYME)는 암, 염증 및 자가면역 질환을 위한 다기능 생물 치료제 개발에 중점을 둔 임상 단계의 생명공학 회사로, 두 개의 주요 투자자 회의에 참여할 것이라고 발표했습니다.
회사는 Needham 24th Annual Virtual Healthcare Conference에 참석하며, 경영진은 4월 8일 오전 9시 30분 ET에 1:1 회의를 진행하고 발표를 할 예정입니다. 또한, Zymeworks는 4월 9일 오후 12시 30분 ET에 Stifel 2025 Virtual Targeted Oncology Forum에 참여하여 1:1 회의와 담소를 나눌 것입니다.
Zymeworks (Nasdaq: ZYME), une entreprise biopharmaceutique en phase clinique axée sur le développement de biothérapeutiques multifonctionnels pour le cancer, l'inflammation et les maladies auto-immunes, a annoncé sa participation à deux grandes conférences pour investisseurs à venir.
L'entreprise sera présente à la Needham 24th Annual Virtual Healthcare Conference, où la direction tiendra des réunions individuelles et fera une présentation le 8 avril à 9h30 ET. De plus, Zymeworks participera au Stifel 2025 Virtual Targeted Oncology Forum le 9 avril à 12h30 ET, avec des réunions individuelles et une discussion informelle.
Zymeworks (Nasdaq: ZYME), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung multifunktionaler Biotherapeutika für Krebs, Entzündungen und Autoimmunerkrankungen konzentriert, hat seine Teilnahme an zwei wichtigen bevorstehenden Investorenkonferenzen angekündigt.
Das Unternehmen wird an der Needham 24th Annual Virtual Healthcare Conference teilnehmen, wo das Management Einzelgespräche führen und am 8. April um 9:30 Uhr ET eine Präsentation halten wird. Darüber hinaus wird Zymeworks am 9. April um 12:30 Uhr ET am Stifel 2025 Virtual Targeted Oncology Forum teilnehmen, das Einzelgespräche und ein informelles Gespräch umfasst.
- None.
- None.
VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences:
- Needham 24th Annual Virtual Healthcare Conference: Zymeworks’ management will participate in virtual one-on-one meetings and present on April 8 at 9:30 am Eastern Time (ET).
- Stifel 2025 Virtual Targeted Oncology Forum: Zymeworks’ management will participate in virtual one-on-one meetings and a fireside chat on April 9 at 12:30 pm ET.
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz Pharmaceuticals), granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) second-line biliary tract cancer (BTC). Ziihera® is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. Zanidatamab is currently under regulatory review in the EU and China for second-line BTC and is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with an investigational new drug application for ZW251 planned for mid-2025. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
FAQ
What investor conferences will Zymeworks (ZYME) attend in April 2025?
When is Zymeworks' (ZYME) presentation at the Needham Healthcare Conference?
What type of meetings will Zymeworks (ZYME) conduct at these investor conferences?
What time is Zymeworks' (ZYME) fireside chat at the Stifel Oncology Forum?
